63 related articles for article (PubMed ID: 3300098)
1. [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
Guddat HM; Schnorr D; Zemke F
Z Urol Nephrol; 1987 Mar; 80(3):165-70. PubMed ID: 3300098
[TBL] [Abstract][Full Text] [Related]
2. [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long-term results of a randomized compound study].
Böhm WD; Gorski J; Geissler W; Illig HD; Koch R
Z Urol Nephrol; 1987 Mar; 80(3):159-64. PubMed ID: 2440199
[TBL] [Abstract][Full Text] [Related]
3. [Conservative therapy of prostate cancer using Turisteron].
Schnorr D; Dörner G; Stahl F; Rohde W; Guddat HM
Z Urol Nephrol; 1987 Mar; 80(3):149-57. PubMed ID: 3111122
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron).
Dörner G; Schnorr D; Stahl F; Rohde W
Exp Clin Endocrinol; 1985 Dec; 86(2):190-6. PubMed ID: 3912197
[TBL] [Abstract][Full Text] [Related]
5. [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
Drawz B; Hoffmann L; Drawz G; Russbüldt R
Z Urol Nephrol; 1987 Mar; 80(3):171-5. PubMed ID: 3604473
[TBL] [Abstract][Full Text] [Related]
6. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rhode W
Z Urol Nephrol; 1987 Mar; 80(3):125-33. PubMed ID: 3604471
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experience using Turisteron in the treatment of prostatic cancer].
Sladczyk E
Z Urol Nephrol; 1987 Mar; 80(3):181-3. PubMed ID: 3604475
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
Stahl F; Schnorr D; Rohde W; Dörner G
Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
[TBL] [Abstract][Full Text] [Related]
10. [Liver damage in hormone therapy of prostate cancer].
Zade W; Schott H
Z Urol Nephrol; 1987 Mar; 80(3):177-9. PubMed ID: 3604474
[TBL] [Abstract][Full Text] [Related]
11. [Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].
Gorski J; Böhm WD; Illig HD; Koch R
Urologe A; 1988 Sep; 27(5):287-90. PubMed ID: 3051628
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
13. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer.
Stahl F; Schnorr D; Bär CM; Fröhlich G; Dörner G
Exp Clin Endocrinol; 1989; 94(3):239-43. PubMed ID: 2630306
[TBL] [Abstract][Full Text] [Related]
14. [Secondary endocrine therapy with oral estrogen for relapsed prostate cancer].
Onita T; Igawa T; Hisamatsu H; Sakai H; Kanetake H
Hinyokika Kiyo; 2009 Oct; 55(10):595-8. PubMed ID: 19926941
[TBL] [Abstract][Full Text] [Related]
15. [Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)].
Gürtler R; Tanneberger S; Bodek B; Morack G
Arch Geschwulstforsch; 1982; 52(2):129-39. PubMed ID: 7103689
[TBL] [Abstract][Full Text] [Related]
16. [Turisteron in the treatment of advanced carcinoma of the prostate].
Vachalovský V; Vomácka V
Rozhl Chir; 1985 Nov; 64(11):718-22. PubMed ID: 4089702
[No Abstract] [Full Text] [Related]
17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
18. [Initial experience with ethinyl estradiol sulfonate (J 96) in the therapy of prostate carcinoma].
Guddat HM; Schnorr D; Dörner G; Stahl F; Rohde W
Z Urol Nephrol; 1979 Mar; 72(3):153-7. PubMed ID: 380227
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
20. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
